- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03471533
Efficacy of a Natural Ingredient on Blood Pressure (FISTA)
3 oktober 2019 uppdaterad av: Francisco Javier López Román, Universidad Católica San Antonio de Murcia
Clinical Trial and Randomized Efficacy of a Natural Ingredient on the Arterial Tension of Normother Subjects or With Arterial Hypertension Grade i Without Pharmacological Treatment
Randomized controlled trial with two parallel branches (experimental product and placebo), double blind and unicentric with which it is intended to evaluate the efficacy of the product under investigation against placebo on blood pressure of normotensive subjects or with hypertension grade I without Pharmacotherapy.
The subjects that meet the selection criteria will make a total of five visits to the research laboratory and perform the tests that were pre-established in the protocol.
Later, a statistical analysis will be carried out with the variables measured in the study to obtain results.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
80
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Murcia, Spanien, 30107
- Catholic University of Murcia
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 65 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Subjects of both sexes between 18-65 years old.
- Systolic blood pressure between 120 and 159 mmHg or diastolic blood pressure between 80 and 100 mm Hg. taken in basal conditions.
- Volunteers able to understand the clinical study and willing to comply with the procedures and requirements of the study
Exclusion Criteria:
- In pharmacological treatment of arterial hypertension.
- Subjects with acute diseases.
- Volunteers with a history or presence of chronic pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunological, dermatological, urological, neurological, psychiatric, cardiovascular or pathological conditions or malignant tumor disease that can modify the blood pressure of subjects.
- Subjected to major surgery in the last 3 months.
- Subjects who stopped smoking in the last 6 months or who intend to quit during the study.
- Subjects with allergies or eating disorders.
- Participation in another study that includes blood extractions or dietary intervention.
- Pregnant woman.
- Subjects whose condition does not make them eligible for the study, according to the researcher.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Ëxperimental
Consumption during 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg. Two capsules a day will be consumed thirty minutes before breakfast for 84 days. |
84 days of consumption
|
|
Placebo-jämförare: Placebo
Consumption during 84 days of saccharose.
Two capsules a day will be consumed thirty minutes before breakfast for 84 days.
|
84 days of consumption
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Assessing a change of blood pressure five times
Tidsram: Blood pressure measurements will be taken with a Holter on five separate occasions and for 24 hours each day. The measurements will be made at baseline and at 14, 28, 56 and 84 days of consumption of the product.
|
blood pressure is measured with a holter
|
Blood pressure measurements will be taken with a Holter on five separate occasions and for 24 hours each day. The measurements will be made at baseline and at 14, 28, 56 and 84 days of consumption of the product.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
body composition
Tidsram: Two densitometries will be performed. One at the beginning of the test, in basal conditions and another at the end of the test after 84 days of taking the product.e beginning and at the end
|
Dual X-ray absorptiometry (DEXA)
|
Two densitometries will be performed. One at the beginning of the test, in basal conditions and another at the end of the test after 84 days of taking the product.e beginning and at the end
|
|
body composition
Tidsram: A record of body composition will be made five times during the 84 days of consumption. Measures will be taken at baseline, at 14 days, 28, 56 and 84 days.
|
Bioimpedancetry
|
A record of body composition will be made five times during the 84 days of consumption. Measures will be taken at baseline, at 14 days, 28, 56 and 84 days.
|
|
blood samples
Tidsram: Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 84 days of use.
|
Glucidal metabolism and lipid metabolism.
It was measured in milligrams per deciliter.
|
Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 84 days of use.
|
|
Subjective sensation of product consumption
Tidsram: Subjects will complete the hedonic scale four times. at 14, 28, 56 and 84 days of consumption of the product under study.
|
5-point hedonic scale.
There are five points, being 1 I do not like and 5 I like it a lot.
A scale will be passed through paper.
|
Subjects will complete the hedonic scale four times. at 14, 28, 56 and 84 days of consumption of the product under study.
|
|
physical activity
Tidsram: An accelerometer will be placed twice on the subjects. The first time at baseline and the second after taking 84 days of consumption of the product under study.
|
accelerometer
|
An accelerometer will be placed twice on the subjects. The first time at baseline and the second after taking 84 days of consumption of the product under study.
|
|
Control of dietary intake
Tidsram: A nutritional registry will be carried out. The nutritional intake of for days in two periods will be collected. One record at the beginning and another at the end, that is, six days.
|
Diet source
|
A nutritional registry will be carried out. The nutritional intake of for days in two periods will be collected. One record at the beginning and another at the end, that is, six days.
|
|
quality of life questionnaire
Tidsram: The cuestionnaire will be taken twice, once at baseline, at the beginning of the trial and once at the end after 84 days of use. The subjects have to answer 26 items on a scale of one to five, being one never and 5 always.
|
questionnaire: WHOQOL-BREF
|
The cuestionnaire will be taken twice, once at baseline, at the beginning of the trial and once at the end after 84 days of use. The subjects have to answer 26 items on a scale of one to five, being one never and 5 always.
|
|
Gastrointestinal well-being evaluation
Tidsram: The questionnaire will be completed five times (GIQLI). It will be completed at baseline (without consumption of the product), at 14, 28, 56 and 84 days of consumption of the experimental product.
|
Gastrointestinal quality of life questionnaire.
The subjects have to answer 36 items on a scale of one to five, being 1 all the time and 5 never.
|
The questionnaire will be completed five times (GIQLI). It will be completed at baseline (without consumption of the product), at 14, 28, 56 and 84 days of consumption of the experimental product.
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
9 april 2018
Primärt slutförande (Faktisk)
28 februari 2019
Avslutad studie (Faktisk)
30 mars 2019
Studieregistreringsdatum
Först inskickad
27 februari 2018
Först inskickad som uppfyllde QC-kriterierna
19 mars 2018
Första postat (Faktisk)
20 mars 2018
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
4 oktober 2019
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
3 oktober 2019
Senast verifierad
1 oktober 2019
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- UCAM-CFE-0001
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .